Premium
Angiotensin II antagonists—saralasin
Author(s) -
Moore Alan F.,
Fulton Robert W.
Publication year - 1984
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430040309
Subject(s) - saralasin , angiotensin ii , renin–angiotensin system , angiotensin receptor , agonist , pharmacology , in vivo , endocrinology , medicine , receptor , chemistry , blood pressure , biology , microbiology and biotechnology
Abstract Saralasin is the only marketed member of a class of compounds described as angiotensin II receptor antagonists. Its pharmacology is characterized by three general properties: (1) no actions unrelated to the renin‐angiotensin system; (2) a small partial agonist effect in some tissues in vitro and in some animal models in vivo, and (3) a blood‐pressure lowering response to saralasin evident only in animals with an activated endogenous renin angiotensin system. It is suggested that the natriuretic effect of angiotensin II mediated via central nervous system (CNS) mechanisms may be future productive area of research in which to study the actions of angiotensin II antagonists.